Your weight loss journey is going well: Youre losing body fat and youre starting to feel healthier
MASH confers excess risk not only for cardiovascular disease but also for chronic kidney disease (CKD) and several extra-hepatic malignancies [56, 57]
A second-generation glucagon-like peptide-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models
cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina) occurred in 109 participants
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
The difference, increasingly, comes down to which medication class a person chooses, how that medication interacts with their specific biology, and whether the treatment timeline matches their actual goals